BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 11173047)

  • 1. Cyclooxygenase inhibition and thrombogenicity.
    Catella-Lawson F; Crofford LJ
    Am J Med; 2001 Feb; 110 Suppl 3A():28S-32S. PubMed ID: 11173047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current perspective on the cardiovascular effects of coxibs.
    Konstam MA; Weir MR
    Cleve Clin J Med; 2002; 69 Suppl 1():SI47-52. PubMed ID: 12086293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs.
    Patrono C; Patrignani P; García Rodríguez LA
    J Clin Invest; 2001 Jul; 108(1):7-13. PubMed ID: 11435450
    [No Abstract]   [Full Text] [Related]  

  • 4. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis.
    Belton O; Byrne D; Kearney D; Leahy A; Fitzgerald DJ
    Circulation; 2000 Aug; 102(8):840-5. PubMed ID: 10952950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COX-2 inhibitors: a review.
    Houston AM; Teach SJ
    Pediatr Emerg Care; 2004 Jun; 20(6):396-9; quiz 400-2. PubMed ID: 15179150
    [No Abstract]   [Full Text] [Related]  

  • 6. The "aspirin" of the new millennium: cyclooxygenase-2 inhibitors.
    Buttar NS; Wang KK
    Mayo Clin Proc; 2000 Oct; 75(10):1027-38. PubMed ID: 11040851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
    Weir MR; Sperling RS; Reicin A; Gertz BJ
    Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs: clinical considerations.
    FitzGerald GA
    Am J Cardiol; 2002 Mar; 89(6A):26D-32D. PubMed ID: 11909558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclooxygenase inhibition in patients with coronary artery disease.
    Frishman WH
    J Am Coll Cardiol; 2004 Feb; 43(4):532-3. PubMed ID: 14975459
    [No Abstract]   [Full Text] [Related]  

  • 10. Nonsteroidal anti-Inflammatory drugs and cardiovascular risk.
    Howard PA; Delafontaine P
    J Am Coll Cardiol; 2004 Feb; 43(4):519-25. PubMed ID: 14975457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An introduction to aspirin, NSAIDs, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part I.
    Moyad MA
    Semin Urol Oncol; 2001 Nov; 19(4):294-305. PubMed ID: 11769881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications.
    Pairet M; Engelhardt G
    Fundam Clin Pharmacol; 1996; 10(1):1-17. PubMed ID: 8900495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of COX-1 and COX-2 in asthma pathogenesis and its significance in the use of selective inhibitors.
    Szczeklik A; Sanak M
    Clin Exp Allergy; 2002 Mar; 32(3):339-42. PubMed ID: 11940059
    [No Abstract]   [Full Text] [Related]  

  • 14. [COX-2 expression in gastric cancers].
    Sakamoto C
    Nihon Rinsho; 2001 Apr; 59 Suppl 4():598-603. PubMed ID: 11424449
    [No Abstract]   [Full Text] [Related]  

  • 15. Cardiovascular events and COX-2 inhibitors.
    McGeer PL; McGeer EG; Yasojima K
    JAMA; 2001 Dec; 286(22):2810; author reply 2811-2. PubMed ID: 11735747
    [No Abstract]   [Full Text] [Related]  

  • 16. Why do cyclo-oxygenase-2 inhibitors cause cardiovascular events?
    Bing RJ; Lomnicka M
    J Am Coll Cardiol; 2002 Feb; 39(3):521-2. PubMed ID: 11823092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Introduction. The role of COX-2-specific inhibitors in clinical practice.
    Lipsky PE
    Am J Med; 2001 Feb; 110 Suppl 3A():1S-2S. PubMed ID: 11173042
    [No Abstract]   [Full Text] [Related]  

  • 18. The new NSAIDs: cox-2 inhibitors.
    Capriotti T
    Medsurg Nurs; 2000 Dec; 9(6):313-7. PubMed ID: 11904867
    [No Abstract]   [Full Text] [Related]  

  • 19. COX-2: separating myth from reality.
    McKenna F
    Scand J Rheumatol Suppl; 1999; 109():19-29. PubMed ID: 10422543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacology and clinical action of COX-2 selective NSAIDs.
    Bovill JG
    Adv Exp Med Biol; 2003; 523():201-14. PubMed ID: 15088852
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.